PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer : rationale and design

Show full item record



Permalink

http://hdl.handle.net/10138/309689

Citation

Ahlberg , M S , Adami , H-O , Beckmann , K , Bertilsson , H , Bratt , O , Cahill , D , Egevad , L , Garmo , H , Holmberg , L , Johansson , E , Rannikko , A , Van Hemelrijck , M , Jäderling , F , Wassberg , C , Åberg , U W N & Bill-Axelson , A 2019 , ' PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer : rationale and design ' , BMJ Open , vol. 9 , no. 8 , e027860 . https://doi.org/10.1136/bmjopen-2018-027860

Title: PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer : rationale and design
Author: Ahlberg, Mats Steinholtz; Adami, Hans-Olov; Beckmann, Kerri; Bertilsson, Helena; Bratt, Ola; Cahill, Declan; Egevad, Lars; Garmo, Hans; Holmberg, Lars; Johansson, Eva; Rannikko, Antti; Van Hemelrijck, Mieke; Jäderling, Fredrik; Wassberg, Cecilia; Åberg, Ulrika W. N.; Bill-Axelson, Anna
Contributor organization: University of Helsinki
Department of Surgery
University Management
Urologian yksikkö
HUS Abdominal Center
Date: 2019-08
Language: eng
Number of pages: 7
Belongs to series: BMJ Open
ISSN: 2044-6055
DOI: https://doi.org/10.1136/bmjopen-2018-027860
URI: http://hdl.handle.net/10138/309689
Abstract: Introduction Overtreatment of localised prostate cancer is substantial despite increased use of active surveillance. No randomised trials help define how to monitor patients or when to initiate treatment with curative intent. Methods and analysis A randomised, multicentre, intervention trial designed to evaluate the safety of an MRI-based active surveillance protocol, with standardised triggers for repeated biopsies and radical treatment. The aim is to reduce overtreatment of prostate cancer. 2000 men will be randomly allocated to either surveillance according to current practice or to standardised triggers at centres in Sweden, Norway, Finland and the UK. Men diagnosed in the past 12 months with prostate cancer, 0.2ng/mL/cc, any International Society of Urological Pathology (ISUP) grade 1 are eligible. Men with ISUP grade 2 in Ethics and dissemination Ethical approval was obtained in each participating country. Results for the primary and secondary outcome measures will be submitted for publication in peer-reviewed journals. Trial registration number NCT02914873.
Subject: active surveillance
MRI
prostate cancer
randomised trial
FOLLOW-UP
ACCURACY
VERSION
LIFE
3126 Surgery, anesthesiology, intensive care, radiology
3122 Cancers
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
e027860.full.pdf 406.2Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record